title: [A case of hepatocellular carcinoma with bone metastasis responding to concurrent TS-1/low-dose cisplatin (CDDP) therapy and radiotherapy].
abstract: A standard treatment for hepatocellular carcinoma with extrahepatic metastasis is not established and chemotherapy is ineffective. We experienced a case of hepatocellular carcinoma with bone metastasis that responded to concurrent TS-1/low-dose cisplatin (CDDP) therapy and radiotherapy. A 58-year-old male patient with left iliac bone metastasis after 2 hepatectomies was admitted to our hospital. The titer of serum AFP and PIVKA-II showed an extremely high levels, 12,350.5 ng/ml and 993 mAU/ml, respectively. The uptake area was found at the left iliac bone by scintigraphy with 99mTc-HMDP. Treatment with TS-1/low-dose CDDP therapy and radiotherapy (36 Gy) was started concurrently. The chemotherapy regimen comprised daily oral administration of 100 mg of TS-1 for 21 days and CDDP 10 mg/body infusion (day 1-5, 8-12). An additional 2 courses of TS-1/low-dose CDDP therapy were repeated. After that, severe pain diminished and the titer of serum showed AFP and PIVKA-II had improved to within normal ranges. The uptake at the left iliac bone was found to have decreased by scintigraphy. Adverse events were grade 1 nausea and leucopenia. TS-1/low-dose CDDP therapy seems to be applicable for the treatment of hepatocellular carcinoma with bone metastasis.
authors.affiliation: Division of Surgery, Japan Self Defense Force Central Hospital.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Suganuma
authors.forename: Risa
authors.initials: R
authors.lastname: Terauchi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Shikina
authors.forename: Masafumi
authors.initials: M
authors.lastname: Tanaka
authors.forename: Suefumi
authors.initials: S
authors.lastname: Aozasa
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Utsunomiya
authors.forename: Keiichi
authors.initials: K
authors.lastname: Fujino
authors.forename: Hideto
authors.initials: H
authors.lastname: Ito
authors.forename: Kazushige
authors.initials: K
authors.lastname: Okada
authors.forename: Tomoki
authors.initials: T
authors.lastname: Tsuda
authors.forename: Kazuo
authors.initials: K
authors.lastname: Hase
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D002945:Cisplatin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006498:Hepatectomy; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000473:pathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D011498:Protein Precursors / Q000097:blood; D011516:Prothrombin; D011725:Pyridines / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D015415:Biomarkers; D014408:Biomarkers, Tumor; D004338:Drug Combinations; D011498:Protein Precursors; D011725:Pyridines; D000509:alpha-Fetoproteins; C079198:S 1 (combination); D005641:Tegafur; C008208:acarboxyprothrombin; D010094:Oxonic Acid; D011516:Prothrombin; D002945:Cisplatin